Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

Leukemia

Volumn 27, Issue 12, 2013, Pages 2357-2365

  Schmidt, J ^a   Braggio, E ^a   Kortuem, K M ^a   Egan, J B ^a   Zhu, Y X ^a   Xin, C S ^a   Tiedemann, R E ^a   Palmer, S E ^a   Garbitt, V M ^a   McCauley, D ^b   Kauffman, M ^c   Shacham, S ^c   Chesi, M ^a   Bergsagel, P L ^a   Stewart, A K ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Karyopharm Therapeutics   (United States)

Author keywords

CRM1; CRM1 Inhibitors; exportin; KPT 276; Myeloma; XPO1

Indexed keywords

ANTINEOPLASTIC AGENT; BROMODOMAIN CONTAINING PROTEIN 4; CARFILZOMIB; CELL DIVISION CYCLE 25 HOMOLOG A; EXPORTIN 1; KPT 276; MELPHALAN; PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL CYCLE ARREST; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IC 50; MONOCLONAL IMMUNOGLOBULINEMIA; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; ONCOGENE C MYC; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TREATMENT DURATION; TUMOR XENOGRAFT; WEIGHT REDUCTION; WESTERN BLOTTING;

ACRYLAMIDES; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL NUCLEUS; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KARYOPHERINS; MICE; MULTIPLE MYELOMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890442009     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.172     Document Type: Article

References (33)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
3. Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res 2012; 72: 757-768.
4. Pellom Jr ST, Shanker A. Development of proteasome inhibitors as therapeutic drugs. J Clin Cell Immunol 2012; S5: 5.
5. Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 2012; 23: 3673-3676.
6. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021-1032.
7. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012; 120: 4621-4634.
8. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009; 21: 229-235.
9. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Inv Med 2009; 32: E315.
10. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008; 112: 1733-1743.
11. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009; 65: 153-159, discussion 159-160.
12. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exper Hematol 2013; 41: 67-78 e64.
13. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 2013; e-pub ahead of print 16 April 2013; doi:10.1038/leu.2013.115.
14. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74: 648-649.
15. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011; 118: 3922-3931.
16. Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009; 69: 6899-6905.
17. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013; 161: 117-127.
18. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013; 27: 66-74.
19. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012; 120: 1765-1773.
20. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP et al. CRM1 Blockade by Selective Inhibitors of Nuclear Export (SINE) attenuates Kidney Cancer Growth. J Urol 2012; 189: 2317-2326.
21. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M et al. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2012; S0016-5085: 01552-1.
22. Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012; 120: 376-385.
23. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-6338.
24. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
25. Kandarpa M, Kraftson SJ, Maxwell SP, McCauley D, Shacham S, Kauffman M et al. CRM1 is highly expressed in myeloma plasma cells and its inhibition by KPT-SINE induces cytotoxicity by increasing p53 in the nucleus of multiple myeloma (MM) cells. ASH Annu Meet Abstr 2011, 118: 1852.
26. Kong S-Y, Landesman Y, Jakubikova J, Sellitto MA, Cagnetta A, Cea M et al. Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma. ASH Annu Meet Abstr 2011, 118: 2913.
27. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187.
28. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-1035.
29. Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001; 490: 117-122.
30. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996; 382: 511-517.
31. Gabrea A, Leif Bergsagel P, Michael Kuehl W. Distinguishing primary and secondary translocations in multiple myeloma. DNA Repair 2006; 5: 1225-1233.
32. Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007; 282: 13141-13145.
33. Mochizuki K, Nishiyama A, Jang MK, Dey A, Ghosh A, Tamura T et al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J Biol Chem 2008; 283: 9040-9048.